| Business Summary | | NPS
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
with
headquarters
in
Salt
Lake
City,
Utah,
and
additional
operations
in
Toronto,
Ontario,
Canada.
The
Company
discovers,
develops
and
intends
to
commercialize
small
molecule
drugs
and
recombinant
proteins,
primarily
for
bone
and
mineral
disorders
and
central
nervous
system
disorders.
The
Company
has
five
drugs
in
clinical
development
and
several
preclinical
product
candidates.
The
Company's
two
most
advanced
product
candidates
focus
on
bone
and
mineral
disorders.
They
are
AMG
073,
which
has
completed
a
series
of
Phase
II
clinical
trials
for
treatment
of
hyperparathyroidism,
and
ALX1-11,
which
is
in
a
pivotal
Phase
III
clinical
trial
for
treatment
of
post-menopausal
osteoporosis. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NPSP
is
engaged
in
the
discovery
and
development
of
prescription
drugs
that
are
intended
to
be
active
on
selected
biological
targets,
including
ion
channels,
cell
surface
receptors
and
other
metabolic
pathways.
For
the
six
months
ended
6/01,
revenues
decreased
76%
to
$982
thousand.
Net
loss
before
accounting
change
rose
23%
to
$22.2
million.
Revenues
reflect
the
expiration
of
R&D
support
payments.
Higher
loss
also
reflect
increased
research
and
development
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Hunter Jackson, Ph.D., 50 CEO,
Pres and Chairman | $280K | -- | Robert Merrell, 44 VP
of Fin., CFO, and Treasurer | 160K | $204K | David Clark, 46 VP,
Operations, Bus. Devel. and Corp. Communications | -- | -- | James Jensen, 55 VP
of Corp. Devel. and Legal Affairs Sec., | 188K | -- | N. Patricia Freston, Ph.D., 60 VP
of HR | -- | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|